ⓘ Small modular immunopharmaceutical

                                     

ⓘ Small modular immunopharmaceutical

Small modular immunopharmaceuticals, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies, and like them have a binding site for antigens that could be used for monoclonal antibody therapy. SMIPs have similar biological half-life and, being smaller than antibodies, are reasoned to have better tissue penetration properties. They were invented by Trubion and are now being developed by Emergent BioSolutions, which acquired Trubion in 2010.

                                     
  • TRU - ADhanCe potency enhancing technology for immunopharmaceuticals SMIP, or small modular immunopharmaceutical therapeutics are single chain polypeptides
  • CD37 - positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood. 110 7 2569 77. doi: 10.1182 blood - 2006 - 12 - 062927